# Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

> **NCT05005299** · PHASE1 · UNKNOWN · sponsor: **Melbourne Health** · enrollment: 18 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute
- Leukemia, Lymphoblastic, Acute, L1
- Leukemia, Lymphoblastic, Acute, L2
- Myelodysplastic Syndromes
- Non-hodgkin Lymphoma
- Plasma Cell Myeloma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05005299
- **Lead sponsor:** Melbourne Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-08
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05005299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05005299, "Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05005299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*